Cagrilintide

Phase 3Peptide

Cagrilintide is used to help people with type 2 diabetes control their blood sugar levels and lose weight by slowing down how quickly food moves through the stomach.[1] Cagrilintide is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]

Cagrilintide is one of 264 peptide programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

263

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Weight LossActive, not recruiting

Liver DiseaseActive, not recruiting

Heart FailureActive, not recruiting

Type 2 DiabetesRecruiting

ObesityActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Overweight Body Mass Index StatusActive, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Weight LossPhase 3

Active, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

Type 2 DiabetesPhase 2

Recruiting

ObesityPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Overweight Body Mass Index StatusPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Cagrilintide

Novo Nordisk

Phase 3

7 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 5

Forxiga

AstraZeneca

Preclinical

3 6

Lovaza

AstraZeneca

Preclinical

1 7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 9

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Heart Failure

NCT04982575

Q4 2026

Phase 3Active, not recruiting

Body Weight

NCT05567796

Q1 2027

Phase 1Not yet recruiting

Overweight

NCT07411560

Q2 2027

Phase 3Active, not recruiting

Obesity

NCT07220642

Phase 3Active, not recruiting

Type 2 Diabetes

NCT07220759

Clinical

Trials by Indication[1]

Body Weight7 trials

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05567796·3,400 enrolled

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07253285·460 enrolled

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06267092·164 enrolled

Show 4 more trials

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813925·331 enrolled

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05996848·300 enrolled

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06207877·62 enrolled

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06388187·300 enrolled

Type 2 Diabetes7 trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323161·274 enrolled

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05394519·1,200 enrolled

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06221969·1,000 enrolled

Show 4 more trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323174·189 enrolled

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07220759·330 enrolled

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06403761·158 enrolled

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06534411·1,023 enrolled

Overweight3 trials

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06719011·177 enrolled

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07411560·100 enrolled

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04940078·40 enrolled

Obesity3 trials

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06131437·809 enrolled

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07220642·300 enrolled

Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07607587·114 enrolled

Heart2 trials

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05669755·7,101 enrolled

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05804162·107 enrolled

8 more indications

Weight loss1 trial

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06780449·400 enrolled

Chronic Kidney Disease1 trial

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06131372·626 enrolled

Single Dose1 trial

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05564104·32 enrolled

Metabolism1 trial

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07010432·144 enrolled

Liver Disease1 trial

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06409130·270 enrolled

Atorvastatin1 trial

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06065540·2,734 enrolled

Heart Failure1 trial

HELIOS-B: Patisiran in Heart Failure with ATTR-CM

Active, not recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 3·NCT04982575·655 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Cagrilintide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cagrilintide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cagrilintide. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 10 publications indexed for Cagrilintide. U.S. National Library of Medicine.
[5]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Amylin Analog[2]
Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

Key Publications[4]

Longitudinal monitoring of pulpal and periapical health of adjacent natural teeth during the implant healing period: a prospective cohort study.

BMC Oral HealthJul 14, 2026DOI: 10.1186/s12903-026-09211-8

Diagnostic confirmation of adult sinonasal rhabdomyosarcoma through comprehensive immunohistochemical profiling: a case report.

BMC SurgJul 13, 2026DOI: 10.1186/s12893-026-04032-6

Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.

BMC Health Serv ResJul 13, 2026DOI: 10.1186/s12913-026-15081-1

Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.

BMC UrolJul 13, 2026DOI: 10.1186/s12894-026-02249-4

Quercetin-loaded PCL scaffold suppresses bone metastatic tumors and augments in situ bone formation.

BMC BiotechnolJul 13, 2026DOI: 10.1186/s12896-026-01198-y

Latent profile analysis of health-related quality of life in patients with bladder cancer and abdominal wall stomas: a multicenter cross-sectional study.

BMC UrolJul 13, 2026DOI: 10.1186/s12894-026-02253-8

Oral health services use among adults in Brazil: inequities and the role of SUS in mitigating them (SB Brasil 2023).

BMC Oral HealthJul 13, 2026DOI: 10.1186/s12903-026-09239-w

Hip range of motion is differentially associated with pain sensitivity in individuals with and without knee osteoarthritis.

BMC Musculoskelet DisordJul 13, 2026DOI: 10.1186/s12891-026-10127-1

Understanding the multidimensional barriers to treatment adherence among Iranian patients with hypertension: a qualitative content analysis.

BMC Public HealthJul 13, 2026DOI: 10.1186/s12889-026-28508-5

Successful pregnancy following extensive myomectomy for diffuse uterine leiomyomatosis.

BMC Pregnancy ChildbirthJul 13, 2026DOI: 10.1186/s12884-026-09644-7

Cagrilintide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Body Weight7 trials

Type 2 Diabetes7 trials

Overweight3 trials

Obesity3 trials

Heart2 trials

Weight loss1 trial

Chronic Kidney Disease1 trial

Single Dose1 trial

Metabolism1 trial

Liver Disease1 trial

Atorvastatin1 trial

Type 2 Diabetes Mellitus1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News